eb-203

Small moleculeexperimental

Clinical trial activity

2 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jun 29, 2022 (NCT05538949)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06487039Phase 2Aug 1, 2024EyebioKorea, Inc., Inje University, Kim's Eye Hospital, Seoul, South Korea, Pusan National University, Yeungnam University
NCT05538949Phase 1Jun 29, 2022EyebioKorea, Inc., Inje University
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
EyebioKorea, Inc.For profit2222022
Inje UniversityAcademic/Hospital2022022
Kim's Eye Hospital, Seoul, South KoreaAcademic/Hospital1012024
Pusan National UniversityAcademic/Hospital1012024
Yeungnam UniversityAcademic/Hospital1012024
5 organizations
Page 1 / 1